{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:32:00Z","timestamp":1770330720077,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s12185-017-2239-8","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T05:27:00Z","timestamp":1492061220000},"page":"398-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term treatment with bosutinib in a phase 1\/2 study in Japanese chronic myeloid leukemia patients resistant\/intolerant to prior tyrosine kinase inhibitor treatment"],"prefix":"10.1007","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"key":"2239_CR1","unstructured":"BOSULIF\u00ae bosutinib. New York: Pfizer Labs, Pfizer Inc; 2016."},{"key":"2239_CR2","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2010.79","volume":"24","author":"S Redaelli","year":"2010","unstructured":"Redaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, Gambacorti-Passerini C. Synergistic activity of the Src\/Abl inhibitor bosutinib in combination with imatinib. Leukemia. 2010;24:1223\u20137.","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"2239_CR3","first-page":"S3","volume":"38","author":"JY Blay","year":"2011","unstructured":"Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011;38(Suppl 1):S3\u20139.","journal-title":"Semin Oncol"},{"key":"2239_CR4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2174\/138945011794751591","volume":"12","author":"A Gnoni","year":"2011","unstructured":"Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets. 2011;12:563\u201378.","journal-title":"Curr Drug Targets"},{"key":"2239_CR5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/S0140-6736(03)13554-4","volume":"361","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003;361:1954\u20136.","journal-title":"Lancet"},{"key":"2239_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","volume":"103","author":"K Bartolovic","year":"2004","unstructured":"Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood. 2004;103:523\u20139.","journal-title":"Blood"},{"key":"2239_CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.13801","volume":"172","author":"TH Brummendorf","year":"2016","unstructured":"Brummendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim DW, Schafhausen P, et al. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016;172:97\u2013110.","journal-title":"Br J Haematol"},{"key":"2239_CR8","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood"},{"key":"2239_CR9","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486\u201392.","journal-title":"J Clin Oncol"},{"key":"2239_CR10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brummendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755\u201368.","journal-title":"Am J Hematol"},{"key":"2239_CR11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood"},{"key":"2239_CR12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12185-014-1722-8","volume":"101","author":"C Nakaseko","year":"2015","unstructured":"Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, et al. A phase 1\/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol. 2015;101:154\u201364.","journal-title":"Int J Hematol"},{"key":"2239_CR13","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87:E125\u20138.","journal-title":"Am J Hematol"},{"key":"2239_CR14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol. 2009;27:469\u201371.","journal-title":"J Clin Oncol"},{"key":"2239_CR15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","volume":"89","author":"C Gambacorti-Passerini","year":"2014","unstructured":"Gambacorti-Passerini C, Brummendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89:732\u201342.","journal-title":"Am J Hematol"},{"key":"2239_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11:71\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"2239_CR17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57:1300\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2239_CR18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogne JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332.","journal-title":"JAMA Oncol"},{"key":"2239_CR19","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207\u201318.","journal-title":"J Clin Invest."},{"key":"2239_CR20","unstructured":"Sprycel\u00ae dasatinib. Princeton: Bristol-Myers Squibb; 2015."},{"key":"2239_CR21","unstructured":"Tasigna\u00ae nilotinib East. Hanover: Novartis Pharmaceuticals Corporation; 2015."},{"key":"2239_CR22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12185-009-0260-2","volume":"89","author":"H Sakamaki","year":"2009","unstructured":"Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase 1\/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89:332\u201341.","journal-title":"Int J Hematol"},{"key":"2239_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12185-012-1026-9","volume":"95","author":"K Usuki","year":"2012","unstructured":"Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 2012;95:409\u201319.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2239-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2239-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2239-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T14:55:16Z","timestamp":1503327316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2239-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2239-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}